Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
Recruiting · NCT06629207 · Interventional (participants receive a specific treatment) · Lead sponsor: Insel Gruppe AG, University Hospital Bern
View the official record on ClinicalTrials.gov →Interventions studied
MRIPET/CT with 18-FDGSPECT : 123 I-FP-CIT (DATSCAN)
What this trial is about
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders
- Written informed consent
Exclusion criteria
- Known diagnosis of PD or other neurodegenerative disorder
- Unequivocal signs of parkinsonism on examination
- Narcolepsy or other known causes of RBD
- Moderate to severe obstructive sleep apnea
- Abnormal neurological or MRI examination
Where it is running
1 location listed.
- Inselspital, University Clinic for Nuclear Medicine - Bern, Switzerland